Korro Bio (KRRO) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Korro Bio (NASDAQ:KRRO) is set to announce its Q2 2025 earnings on August 12, with expected earnings of ($2.54) per share and revenue of $0.41 million.
• Previously, Korro Bio reported ($2.49) earnings per share in May, exceeding analyst expectations and generating $2.55 million in revenue, significantly higher than predicted.
• Analysts have mixed price targets for Korro Bio, with a consensus rating of "Buy" and an average price target of $102.43, reflecting optimism about the company's future performance.

Korro Bio (NASDAQ:KRRO - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($2.54) per share and revenue of $0.41 million for the quarter.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, topping the consensus estimate of ($2.60) by $0.11. The company had revenue of $2.55 million for the quarter, compared to the consensus estimate of $0.13 million. On average, analysts expect Korro Bio to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Korro Bio Trading Up 1.0%

Shares of Korro Bio stock traded up $0.16 on Thursday, reaching $15.86. 84,731 shares of the company were exchanged, compared to its average volume of 122,763. Korro Bio has a fifty-two week low of $10.29 and a fifty-two week high of $98.00. The firm has a market capitalization of $148.93 million, a price-to-earnings ratio of -1.68 and a beta of 2.51. The stock has a fifty day moving average price of $13.57 and a 200-day moving average price of $19.08.

Analysts Set New Price Targets

Several research analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Korro Bio in a report on Thursday, July 24th. Cantor Fitzgerald upgraded shares of Korro Bio to a "strong-buy" rating in a research report on Tuesday, April 29th. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Korro Bio in a research note on Tuesday, May 13th. Finally, Oppenheimer lowered their price objective on shares of Korro Bio from $155.00 to $90.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Korro Bio has an average rating of "Buy" and an average price target of $102.43.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).